TY - JOUR
T1 - Pluripotent Stem Cells in Clinical Cell Transplantation
T2 - Focusing on Induced Pluripotent Stem Cell-Derived RPE Cell Therapy in Age-Related Macular Degeneration
AU - Yang, Yi Ping
AU - Hsiao, Yu Jer
AU - Chang, Kao Jung
AU - Foustine, Shania
AU - Ko, Yu Ling
AU - Tsai, Yi Ching
AU - Tai, Hsiao Yun
AU - Ko, Yu Chieh
AU - Chiou, Shih Hwa
AU - Lin, Tai Chi
AU - Chen, Shih Jen
AU - Chien, Yueh
AU - Hwang, De Kuang
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/11
Y1 - 2022/11
N2 - Human pluripotent stem cells (PSCs), including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represent valuable cell sources to replace diseased or injured tissues in regenerative medicine. iPSCs exhibit the potential for indefinite self-renewal and differentiation into various cell types and can be reprogrammed from somatic tissue that can be easily obtained, paving the way for cell therapy, regenerative medicine, and personalized medicine. Cell therapies using various iPSC-derived cell types are now evolving rapidly for the treatment of clinical diseases, including Parkinson’s disease, hematological diseases, cardiomyopathy, osteoarthritis, and retinal diseases. Since the first interventional clinical trial with autologous iPSC-derived retinal pigment epithelial cells (RPEs) for the treatment of age-related macular degeneration (AMD) was accomplished in Japan, several preclinical trials using iPSC suspensions or monolayers have been launched, or are ongoing or completed. The evolution and generation of human leukocyte antigen (HLA)-universal iPSCs may facilitate the clinical application of iPSC-based therapies. Thus, iPSCs hold great promise in the treatment of multiple retinal diseases. The efficacy and adverse effects of iPSC-based retinal therapies should be carefully assessed in ongoing and further clinical trials.
AB - Human pluripotent stem cells (PSCs), including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represent valuable cell sources to replace diseased or injured tissues in regenerative medicine. iPSCs exhibit the potential for indefinite self-renewal and differentiation into various cell types and can be reprogrammed from somatic tissue that can be easily obtained, paving the way for cell therapy, regenerative medicine, and personalized medicine. Cell therapies using various iPSC-derived cell types are now evolving rapidly for the treatment of clinical diseases, including Parkinson’s disease, hematological diseases, cardiomyopathy, osteoarthritis, and retinal diseases. Since the first interventional clinical trial with autologous iPSC-derived retinal pigment epithelial cells (RPEs) for the treatment of age-related macular degeneration (AMD) was accomplished in Japan, several preclinical trials using iPSC suspensions or monolayers have been launched, or are ongoing or completed. The evolution and generation of human leukocyte antigen (HLA)-universal iPSCs may facilitate the clinical application of iPSC-based therapies. Thus, iPSCs hold great promise in the treatment of multiple retinal diseases. The efficacy and adverse effects of iPSC-based retinal therapies should be carefully assessed in ongoing and further clinical trials.
KW - age-related macular degeneration
KW - cell transplantation
KW - clinical trials
KW - embryonic stem cells
KW - induced pluripotent stem cell
KW - pluripotent stem cells
KW - retinal pigment epithelial cells
UR - http://www.scopus.com/inward/record.url?scp=85142621696&partnerID=8YFLogxK
U2 - 10.3390/ijms232213794
DO - 10.3390/ijms232213794
M3 - Review article
C2 - 36430270
AN - SCOPUS:85142621696
SN - 1661-6596
VL - 23
JO - International Journal Of Molecular Sciences
JF - International Journal Of Molecular Sciences
IS - 22
M1 - 13794
ER -
